Available clinical research studies

Clinical Research is vital to advancements in the field of health care. Research is the cornerstone for investigating disease prevention, treatment using drugs or medical devices, and other interventions.

The Clinical Research department at Aurora BayCare Medical Center offers a variety of clinical research studies:

  • Neuroscience
  • Multiple sclerosis
  • Parkinson's disease
  • Epilepsy
  • Oncology
  • Cardiology
  • Pulmonology

For more information on clinical research studies, call Annette at 920-288-3127. Some of Aurora BayCare Medical Center's open research studies are listed below.

Breast

In-House Registry
Mammosite Patient Registry - Gathering information on the effectiveness of the Mammosite device, cosmetic outcome and toxicities.

NSABP B-39/RTOG 0413
A Randomized Phase III Study of Conventional Whole breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0,I, or II Breast Cancer; NSABP B-39/ RTOG 0413

Genomic –GHI – 0175 registry protocol
A Pilot Phase Observational Registry Study to Evaluate the Baseline Measurements and Patterns of Adjuvant and Neoadjuvant Treatment in Patients for Whom an Oncotype DX® Breast Cancer Recurrence Score Is Obtained 01-075

ECOG 5103
A Double-Blind Phase III trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer. E5103

CALBG 40503
Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer

NSABP B 43
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Wyeth 3004
A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women with Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer

SWOG 0221
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer

ACOSOG Z1071
A Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T0-4, N1-2, M0) at Initial Diagnosis

Colon

CALGB 80702
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer

CALGB 80405 Metastatic
A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

ECOG 5202 L-09-38
A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers; E5202

GYN

GOG 0252
A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(s): Bevacizumab

GOG 0256
A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer

GOG 0235
A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy

Head & Neck

ECOG 1305
A Phase III Randomized Trial of Cisplatin and Docetaxel with or without Bevacizumab In Patients with Recurrent or Metastatic Head and Neck Cancer

Lung

ECOG 1505
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

SWOG 0819
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC); S0819

AMGEN 20070782
A Randomized, Double -blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Admininstered at 500 ug Once-Every-3-weeks in Anemic Subjects With Advanced Stage None-small Cell Lung Cancer Receving Multi-cycle Chemotherapy

Lymphoma

Genetech A phase III multicenter, open-label study of Rituximab faster infusion time in patients with previously untreatable dissue large B cell or Follicular non-hodgkin's lymphona

MDS

AMGEN 20060198
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS). Protocol number 20060198.

AMGEN 20060197
An Open Label Extension Study Evaluating the Safety in Long Term Dosing of Romiplostim (formerly AMG 531) in Thrombocytopenic Subjects with Myelodysplastic Syndrome (MDS)

Metastatic

CALGB 70604
A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer of the breast, prostate or multiple myeloma

Neurology

L-07-205E TYGRIS
TYSABRI Global Observation Program in Safety

09-208 PM 103 ANDANTE
ANDANTE study for suboptimal responders to dopamin agonist for Azilect Add on therapy

10-67n STRATIFY 2
JCV Antibody Program in patients with RRMS

Peripheral Neuropathy

CALGB 170601
A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN); CALGB 170601

Prostate

ECOG 3805 CHAARTED
CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

CALGB 90202
Metastatic A Randomized, Double-Blind, Placebo-Controlled Phase III Study Of Early Versus Standard Zoledronic Acid To Prevent Skeletal Related Events In Men With Prostate Cancer Metastatic To Bone